Saw palmetto supplement use and prostate cancer risk

Nutrition and Cancer

Volumn 55, Issue 1, 2006, Pages 21-27

  Bonnar Pizzorno, Raven M ^a   Littman, Alyson J ^b,c   Kestin, Mark ^a   White, Emily ^b  

^a BASTYR UNIVERSITY   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c Fred Hutchinson Cancer Research Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DOXAZOSIN; FINASTERIDE; MULTIVITAMIN; SABAL EXTRACT; SELENIUM; TAMSULOSIN; TERAZOSIN;

ADULT; AGED; APOPTOSIS; ARTICLE; CANCER INHIBITION; CANCER REGISTRY; CANCER RISK; COHORT ANALYSIS; FOLLOW UP; HERB; HUMAN; IN VITRO STUDY; MAJOR CLINICAL STUDY; MALE; PROSPECTIVE STUDY; PROSTATE CANCER; PROSTATE HYPERTROPHY; QUESTIONNAIRE; RISK REDUCTION; SABAL; SYMPTOMATOLOGY; UNITED STATES;

AGED; ANDROGEN ANTAGONISTS; COHORT STUDIES; CONFIDENCE INTERVALS; DIETARY SUPPLEMENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; MALE; MIDDLE AGED; ODDS RATIO; PLANT EXTRACTS; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; PROSTATIC HYPERPLASIA; PROSTATIC NEOPLASMS; QUESTIONNAIRES; WASHINGTON;

SERENOA REPENS;

EID: 33749183134     PISSN: 01635581     EISSN: None     Source Type: Journal    
DOI: 10.1207/s15327914nc5501_3     Document Type: Article

References (45)

1. Centers for Disease Control and Prevention: Prostate Cancer: The Public Health Perspective. http://www.cdc.gov/cancer/prostate/prostate.htm (Accessed 2004 May 7.)
2. Wilt T, Ishani A, and Mac Donald R: Serenoa repens for benign prostatic hyperplasia. Cochrane Database Syst Rev Issue 3, Art. No. CD001423, 2002.
3. Boyle P, Robertson C, Lowe F, and Roehrborn C: Updated meta-analysis of clinical trials of Serenoa repens extract in the treatment of symptomatic benign prostatic hyperplasia. BJU Int 93, 751-756, 2004.
4. Yankelovich Partners: A Study of Supplement Use. Report prepared for the National Nutritional Foods Association. May 25, 2000.
5. Drugstore.com: http://www.drugstore.com (Accessed 2005 Aug 4.)
6. Bostwick DG, Cooner WH, Denis L, Jones GW, Scardino PT, et al.: The association of benign prostatic hyperplasia and cancer of the prostate. Cancer 70, 291-301, 1992.
7. Chokkalingam AP, Nyren O, Johansson JE, Gridley G, McLaughlin JK, et al.: Prostate carcinoma risk subsequent to diagnosis of benign prostatic hyperplasia: a population-based cohort study in Sweden. Cancer 98, 1727-1734, 2003.
8. Bayne CW, Donnelly F, Ross M, and Habib FK: Serenoa repens (Permixon): a 5a-reductase types I and II inhibitor - new evidence in a coculture model of BPH. Prostate 40, 232-241, 1999.
9. Bayne CW, Ross M, Donnelly F, and Habib FK: The selectivity and specificity of the actions of the lipido-sterolic extract of Serenoa repens (Permixon) on the prostate. J Urol 164, 876-881, 2000.
10. Delos S, Iehle C, Martin PM, and Raynaud JP: Inhibition of the activity of "basic" 5a-reductase (type 1) detected in DU 145 cells and expressed in insect cells. J Steroid Biochem Mol Biol 48, 347-352, 1994.
11. Di Silverio F, Monti S, Sciarra A, Varasano PA, Martini C, et al.: Effects of long-term treatment with Serenoa repens (Permixon) on the concentrations and regional distribution of androgens and epidermal growth factor in benign prostatic hyperplasia. Prostate 37, 77-83, 1998.
12. Habib FK, Ross M, Ho CK, Lyons V, and Chapman K: Serenoa repens (Permixon) inhibits the 5alpha-reductase activity of human prostate cancer cell lines without interfering with PSA expression. Int J Cancer 114, 190-194, 2005.
13. Iehle C, Delos S, Guirou O, Tate R, Raynaud JP, et al.: Human prostatic steroid 5 alpha-reductase isoforms - a comparative study of selective inhibitors. J Steroid Biochem Mol Biol 54, 273-279, 1995.
14. Marks LS, Hess DL, Dorey FJ, Luz Macairan M, Cruz Santos PB, et al.: Tissue effects of saw palmetto and finasteride: use of biopsy cores for in situ quantification of prostatic androgens. Urology 57, 999-1005, 2001.
15. Neiderprum HJ, Schweikert HU, and Zanker KS: Testosterone 5α-reductase inhibition by free fatty acids from Sabal serrulata fruits. Phytomedicine 1, 127, 1994.
16. Raynaud JP, Cousse H, and Martin PM: Inhibition of type 1 and type 2 5alpha-reductase activity by free fatty acids, active ingredients of Permixon. J Steroid Biochem Mol Biol 82, 233-239, 2002.
17. Weisser H, Tunn S, Behnke B, and Krieg M: Effects of the Sabal serrulata extract IDS 89 and its subfractions on 5a-reductase activity in human benign prostatic hyperplasia. Prostate 28, 300-306, 1996.
18. Rhodes L, Primka RL, Berman C, Vergult G, Gabrielm G, et al.: Comparison of finasteride (Proscar) 5 alpha reductase inhibitor, and various commercial plant extracts in in vitro and in vivo 5alpha reductase inhibition. Prostate 22, 43, 1993.
19. Strauch G, Perles P, Vergult G, Gabriel M, Gibelin B, et al.: Comparison of finasteride (Proscar) and Serenoa repens (Permixon) in the inhibition of 5-alpha reductase in healthy male volunteers. Eur Urol 26, 247-252, 1994.
20. Weisser H, Behnke B, Helpap B, Bach D, and Krieg M: Enzyme activities in tissue of human benign prostatic hyperplasia after three months' treatment with the Sabal serrulata extract IDS 89 (Strogen) or placebo. Eur Urol 31, 97-101, 1997.
21. Thompson IM, Goodman PJ, Tangen CM, Lucia MS, Miller GJ, et al.: The influence of finasteride on the development of prostate cancer. N Engl J Med 349, 215-224, 2003.
22. Carilla E, Briley M, Fauran F, Sultan C, and Duvilliers C: Binding of Permixon, a new treatment for prostatic benign hyperplasia, to the cytosolic androgen receptor in the rat prostate. J Steroid Biochem 20, 521-523, 1984.
23. Sultan C, Terraza A, Devillier C, Carilla E, Briley M, et al.: Inhibition of androgen metabolism and binding by a liposterolic extract of "Serenoa repens B" in human foreskin fibroblasts. J Steroid Biochem 20, 515-519, 1984.
24. Di Silverio F, D'Eramo G, Lubrano C, Flammia GP, Sciarra A, et al.: Evidence that Serenoa repens extract displays an antiestrogenic activity in prostatic tissue of benign hypertrophy patients. Eur Urol 21, 309-314, 1992.
25. Paubert-Braquet M, Mencia Huerta JM, Cousse H, and Braquet P: Effect of the lipidic lipidosterolic extract of Serenoa repens (Permixon) on the ionophore A23187-stimulated production of leukotriene B4 (LTB4) from human polymorphonuclear neutrophils. Prostaglandins Leukot Essent Fatty Acids 57, 299-304, 1997.
26. Vela Navarrete R, Garcia Cardoso JV, Barat A, Manzarbeitia F, and Lopez Farre A: BPH and inflammation: pharmacological effects of Permixon on histological and molecular inflammatory markers. Results of a double blind pilot clinical assay. Eur Urol 44, 549-555, 2003.
27. Goldmann WH, Sharma AL, Currier SJ, Johnston PD, Rana A, et al.: Saw palmetto berry extract inhibits cell growth and Cox-2 expression in prostatic cancer cells. Cell Biol Int 25, 1117-1124, 2001.
28. Hsieh TC and Wu JM: Mechanism of action of herbal supplement PC-SPES: elucidation of effects of individual herbs of PC-SPES on proliferation and prostate specific gene expression in androgen-dependent LNCaP cells. Int J Oncol 20, 583-588, 2002.
29. Hill B and Kyprianou N: Effect of permixon on human prostate cell growth: lack of apoptotic action. Prostate 61, 73-80, 2004.
30. Iguchi K, Okumura N, Usui S, Sajiki H, Hirota K, et al.: Myristoleic acid, a cytotoxic component in the extract from Serenoa repens, induces apoptosis and necrosis in human prostatic LNCaP cells. Prostate 47, 59-65, 2001.
31. Ravenna L, Di Silverio F, Russo MA, Salvatori L, Morgante E, et al.: Effects of the lipidosterolic extract of Serenoa repens (Permixon) on human prostatic cell lines. Prostate 29, 219-230, 1996.
32. Delos S, Carsol JL, Ghazarossian E, Raynaud JP, and Martin PM: Testosterone metabolism in primary cultures of human prostate epithelial cells and fibroblasts. J Steroid Biochem Mol Biol 55, 375-383, 1995.
33. Chevalier G, Benard P, Cousse H, and Bengone T: Distribution study of radioactivity in rats after oral administration of the lipido/sterolic extract of Serenoa repens (Permixon) supplemented with [1-14C]-lauric acid, [1-14C]-oleic acid or [4-14C]-betasitosterol. Eur J Drug Metab Pharmacokinet 22, 73-83, 1997.
34. Oh WK, Kantoff PW, Weinberg V, Jones G, Rini BI, et al.: Prospective, multicenter, randomized phase II trial of the herbal supplement, PC-SPES, and diethylstilbestrol in patients with androgen-independent prostate cancer. J Clin Oncol 22, 3705-3712, 2004.
35. Meyer JP and Gillatt DA: PC-SPES: a herbal therapy for the treatment of hormone refractory prostate cancer. Prostate Cancer Prostatic Dis 5, 13-15, 2002.
36. de la Taille A, Hayek OR, Burchardt M, Burchardt T, and Katz AE: Role of herbal compounds (PC-SPES) in hormone-refractory prostate cancer: two case reports. J Altern Complement Med 6, 449-451, 2000.
37. Matlaga B, Hall M, Stindt D, and Torti F: Response of hormone refractory prostate cancer to lycopene. J Urol 166, 613, 2001.
38. Cowan T: Case studies: prostate cancer. Whole Food Nutr J 2, 39-42, 2002.
39. California Department of Health Services: State health director warns consumers about herbal supplements that could cause serious health effects: warning number 02-31. June 5, 2002. http://www.applications.dhs.ca.gov/ pressreleases/store/PressReleases/02-31.html (Accessed 2005 March 19.)
40. White E, Patterson RE, Kristal AR, Thornquist M, King I, et al.: VITamins And Lifestyle cohort study: study design and characteristics of supplement users. Am J Epidemiol 159, 83-93, 2004.
41. Habib FK and Wyllie MG: Not all brands are created equal: a comparison of selected components of different brands of Serenoa repens extract. Prostate Cancer Prostatic Dis 7, 195-200, 2004.
42. Garrard J, Harms S, Eberly LE, and Matiak A: Variations in product choices of frequently purchased herbs: caveat emptor. Arch Intern Med 163, 2290-2295, 2003.
43. Satia-Abouta J, Patterson RE, King IB, Stratton KL, Shattuck AL, et al.: Reliability and validity of self-report of vitamin and mineral supplement use in the Vitamins and Lifestyle study. Am J Epidemiol 157, 944-954, 2003.
44. Schroder FH: Detection of prostate cancer: the impact of the European Randomized Study of Screening for Prostate Cancer (ERSPC). Can J Urol 12, 2-6, 2005.
45. Sarma AV and Schottenfeld D: Prostate cancer incidence, mortality, and survival trends in the United States: 1981-2001. Semin Urol Oncol 20, 3-9, 2002.